1) 6β-hydroxylation
6β-羟基化代谢率
1.
RESULTS:In the study on correlation between F and E 6β-hydroxylation metabolism and the C/D ratio of CsA in renal transplant recipients,there were inverse correlations between 6β-OHF+6β-OHE/F+E and the C/D ratio of CsA,6β-OHF +6β-OHE/F+E and weight-normalized C/D ratio of CsA in all, male and female subjects.
目的:研究肾移植患者尿中氢化可的松(F)及可的松(E)6β-羟基化代谢率与环孢霉素(CsA)血药浓度剂量比的相关性。
2) hydroxylation metabolism
羟基化代谢
1.
Investigation on the hydroxylation metabolism of imrecoxib in vitro by using recombinant human CYPs;
采用重组人源CYP酶研究艾瑞昔布的体外羟基化代谢
3) 6β-hydroxycortisol
6β-羟基氢化可的松
1.
Objective: To investigate the activity of CYP3A enzyme, an effective method of HPLC (Gradient elution)for determining the concentration of 6p-hydroxycortisol and cortisol in urine and measuring the ratio of 6β-hydroxycortisol and cortisol was established.
目的:用HPLC法(梯度洗脱)测定尿液中6β-羟基氢化可的松(6β-OHC)和氢化可的松(HC)的含量,计算6β-OHC和HC的比值以反映人体中CYP3A酶的活性,为其研究提供有效的分析手段。
2.
METHODS After collecting urine for 24 hours,the urinary concentrations of HC and 6β-hydroxycortisol(6β-OHC) were determined by high performance liquid chromatography(HPLC).
方法:收集24h尿液,以HPLC法测定尿液中氢化可的松(HC)与6β-羟基氢化可的松(6β-OHC)的含量,以6β-OHC/HC来评估细胞色素P4503A酶的活性。
3.
The endogenous 6β-hydroxycortisol and cortisol concentrations in the urine were determined.
方法直接收集20例精神病住院患者晨尿液,测定尿液中内源性氢化可的松与6β-羟基氢化可的松的含量,以6β-羟基氢化可的松/氢化可的松来评估CYP3A酶的活性。
4) hyoscyamine 6P-hydroxylase (H6H)
莨菪碱6β-羟基化酶
5) 6β-hydroxyl-testosterone
6β-羟基睾酮
1.
HPLC-UV method was established and validated to determine the productive velocity of metabolite (6β-hydroxyl-testosterone,6β-OHT) of testosterone (as substrate of CYP3A1) and .
采用HPLC法检测以睾酮为探针药物经大鼠肝微粒体温孵后转化的代谢产物6β-羟基睾酮的生成速率来反映大鼠CYP3A1酶的活性。
2.
A HPLC-UV method was established and validated to determine the productive velocity of metabolite(6β-hydroxyl-testosterone,6β-OHT) of testosterone(as substrate of CYP3A1) and to measure the activity of CYP3A1.
采用HPLC检测以睾酮为探针药物经大鼠肝微粒体温孵后转化的代谢产物6β-羟基睾酮的生成速率以评价各组间CYP3A1酶的活性。
6) hydroxyimrecoxib
羟基代谢物
1.
It undergoes extensive metabolism in vivo to its active metabolite-hydroxyimrecoxib.
艾瑞昔布在体内经广泛代谢生成其活性代谢物-艾瑞昔布羟基代谢物。
补充资料：[3-(aminosulfonyl)-4-chloro-N-(2.3-dihydro-2-methyl-1H-indol-1-yl)benzamide]
分子式：C16H16ClN3O3S
分子量：365.5
CAS号：26807-65-8
性质：暂无
制备方法：暂无
用途：用于轻、中度原发性高血压。
分子量：365.5
CAS号：26807-65-8
性质：暂无
制备方法：暂无
用途：用于轻、中度原发性高血压。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条